N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H

Dimitrios Moianos,Maria Makri,Georgia-Myrto Prifti,Aristeidis Chiotellis,Alexandros Pappas,Molly E. Woodson,Razia Tajwar,John E. Tavis,Grigoris Zoidis

DOI: https://doi.org/10.3390/molecules29122942

IF: 4.6

2024-06-21

Molecules

Abstract:Hepatitis B virus (HBV) remains a global health threat. Ribonuclease H (RNase H), part of the virus polymerase protein, cleaves the pgRNA template during viral genome replication. Inhibition of RNase H activity prevents (+) DNA strand synthesis and results in the accumulation of non-functional genomes, terminating the viral replication cycle. RNase H, though promising, remains an under-explored drug target against HBV. We previously reported the identification of a series of N-hydroxypyridinedione (HPD) imines that effectively inhibit the HBV RNase H. In our effort to further explore the HPD scaffold, we designed, synthesized, and evaluated 18 novel HPD oximes, as well as 4 structurally related minoxidil derivatives and 2 barbituric acid counterparts. The new analogs were docked on the RNase H active site and all proved able to coordinate the two Mg2+ ions in the catalytic site. All of the new HPDs effectively inhibited the viral replication in cell assays exhibiting EC50 values in the low μM range (1.1–7.7 μM) with low cytotoxicity, resulting in selectivity indexes (SI) of up to 92, one of the highest reported to date among HBV RNase H inhibitors. Our findings expand the structure–activity relationships on the HPD scaffold, facilitating the development of even more potent anti-HBV agents.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

The paper attempts to address the issue of developing effective inhibitors for Hepatitis B Virus (HBV) RNase H. Specifically, the goals of the paper include: 1. **Exploring new inhibitor structures**: Designing, synthesizing, and evaluating a series of novel N-hydroxy pyridinedione (HPD) oxime compounds and their derivatives to further investigate the potential of the HPD scaffold in inhibiting HBV RNase H. 2. **Enhancing inhibitory effects**: Optimizing the compound structures to improve the inhibitory activity of these inhibitors against HBV RNase H and reduce their cytotoxicity, thereby increasing the selectivity index (SI). 3. **Expanding structure-activity relationships**: Systematically modifying the side chain structures of the compounds to study the effects of different substituents on inhibitory activity, thereby gaining a better understanding of the structure-activity relationships of HPD compounds. Overall, this paper aims to discover more effective HBV RNase H inhibitors through chemical modifications and structural optimization, laying the foundation for the future development of anti-HBV drugs.

N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Inhibition of Hepatitis B Virus Replication by Targeting Ribonucleotide Reductase M2 Protein.

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay

2-Arylthio-5-iodo Pyrimidine Derivatives As Non-Nucleoside HBV Polymerase Inhibitors

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Structure-Based Design of Novel Thiazolone[3,2-a]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy

The hepatitis B virus ribonuclease H as a drug target

Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids.

Design, Synthesis and Biological Evaluation of Thiazolo[3, 2-A]pyrimidine Derivatives As Novel RNase H Inhibitors

Structure-Activity Relationships and Discovery of ( S )-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6 H -pyrido[1,2- h ][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer

5-Iodo-2-arylalkylthio-6-aryl pyrimidin-4(3H)-ones as non-nucleoside anti-HBV agents

Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain

A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation

Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor

The Design And Synthesis Of 9-Phenylcyclohepta[D]Pyrimidine-2,4-Dione Derivatives As Potent Non-Nucleoside Inhibitors Of Hiv Reverse Transcriptase

Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents